Table 3.
Cohort | Hazard ratio (95% CI) | Pvalue |
ER-positive cohort (n = 851) | ||
CMF versus goserelin | 1.00 (0.74–1.36) | 0.99 |
CMF→goserelin versus goserelin | 0.71 (0.51–1.00) | 0.05 |
CMF→goserelin versus CMF | 0.72 (0.51–1.00) | 0.05 |
Age <40 versus ≥40 | 1.50 (1.10–2.06) | 0.01 |
Primary surgical treatment | 0.0002 | |
BCS without RT versus Mast | 2.39 (1.45–3.94) | |
BCS with RT versus Mast | 0.83 (0.63–1.11) | |
Tumor size (cm) | 0.19 | |
1.1–2.0 versus ≤1 | 1.14 (0.73–1.79) | |
>2.1 versus ≤1 | 1.43 (0.90–2.27) | |
Grade | 0.0001 | |
2 versus 1 | 1.75 (1.14–2.70) | |
3 versus 1 | 2.54 (1.63–3.97) | |
ER-negative cohort (n = 205) | ||
CMF versus goserelin | 0.81 (0.46–1.42) | 0.46 |
CMF→goserelin versus goserelin | 0.71 (0.40–1.24) | 0.23 |
CMF→goserelin versus CMF | 0.87 (0.49–1.55) | 0.64 |
Age <40 versus ≥40 | 0.95 (0.56–1.61) | 0.84 |
Primary surgical treatment | 0.69 | |
BCS without RT versus Mast | 1.46 (0.61–3.52) | |
BCS with RT versus Mast | 1.04 (0.63–1.73) | |
Tumor size (cm) | 0.31 | |
1.1–2.0 versus ≤1 | 0.55 (0.26–1.19) | |
>2.1 versus ≤1 | 0.63 (0.29–1.38) | |
Grade | 0.24 | |
2 versus 1 | 1.32 (0.30–5.72) | |
3 versus 1 | 0.82 (0.20–3.39) |
CMF, cyclophosphamide, methotrexate and fluorouracil; CI, confidence interval; RT, radiation therapy; BCS, breast-conserving surgery; Mast, mastectomy.